Nymox completes studies of saliva test for tobacco exposure

By Lisa Kerner

Erie, Pa., Jan. 17 - Nymox Pharmaceutical Corp. announced that studies have been successfully completed for the company's saliva version of the NicAlert test for tobacco exposure.

The studies were undertaken in general medical settings to assess the accuracy and utility of the saliva test. Nymox' saliva test can be used without instruments and can be performed in minutes using several drops of saliva, according to a company news release.

The independent research was supervised by principal investigators, Dr. N. Montalto and Dr. W. Wells.

The studies indicated that the saliva test is easily performed without training, and is accurate, reproducible and highly useful in the general medical setting. The full results from the studies are expected to be presented and published later this year.

Nymox, based in Hasbrouck Heights, N.J., is a biopharmaceutical company specializing in the research and development of therapeutics and diagnostics for the aging population.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.